Optimizing Heparin Quality Assurance Utilizing Electronic Data Abstraction.

Heparin is a high-risk medication with significant variability across patients. Systematic data analysis can help hospitals improve heparin management, ensuring safe and effective anticoagulation. An opportunity exists to create a more efficient data collection process, allowing hospitals to streamline quality assurance programs.

Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients.

Background: A paucity of data exists to support the use of factor (F)Xa inhibitors in severely obese patients with a weight of ≥150 kg or body mass index (BMI) of ≥50 kg/m.

Objectives: The purpose of this study was to evaluate whether FXa inhibitors are as safe and effective as warfarin for the treatment of atrial fibrillation (AF) and/or venous thromboembolism (VTE) in individuals with a BMI of ≥50 kg/m and/or weight of ≥150 kg.

Methods: This was a multicenter retrospective cohort study of severely obese adult patients with AF and/or VTE treated with a FXa inhibitor or warfarin.

Treatment of during extracorporeal life support: A case report.

With rates of ECMO utilization on the rise, prevention of nosocomial infections is of paramount importance. , an emerging highly pathogenic multidrug resistant fungus, is of particular concern as it is associated with persistent colonization of environmental surfaces, inability to be recognized by many diagnostic platforms, inconsistent laboratory susceptibility results, and high mortality rates. We describe a case of in a VV-ECMO patient successfully managed with a combination of anidulafungin, amphotericin B, and flucytosine.

Venous Thromboembolism Prophylaxis in Low Body Weight Critically Ill Patients.

Objective: To compare bleeding and thromboembolic events in low body weight patients receiving reduced-dose venous thromboembolism (VTE) prophylaxis versus standard-dose VTE prophylaxis.

Design: Multicenter, retrospective, cohort study.

Setting: Five Ascension Health Hospitals.

Efficacy and safety of factor Xa inhibitors in low body weight patients.

Study Objective: The purpose of this study is to provide evidence for the safety and efficacy of factor Xa inhibitors in patients with a weight ≤60 kg or BMI < 18.5 kg/m .

Design: Multicenter, retrospective, cohort study.